Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002784063 | SCV003749938 | uncertain significance | Inborn genetic diseases | 2022-12-05 | criteria provided, single submitter | clinical testing | The c.1017C>G (p.D339E) alteration is located in exon 1 (coding exon 1) of the IRF2BPL gene. This alteration results from a C to G substitution at nucleotide position 1017, causing the aspartic acid (D) at amino acid position 339 to be replaced by a glutamic acid (E). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |